Back to search results

Upright MRI for Prostate Cancer Screening

This study is looking at a new way to screen for prostate cancer using an Upright MRI (Magnetic Resonance Imaging) scanner. It compares this new method to the standard PSA (Prostate Specific Antigen) blood test and current MRI imaging. The goal is to see if the Upright MRI is a more effective tool for finding prostate cancer. You might be able to join if you are a man aged 18 to 100, are at risk for prostate cancer, and your doctor has recommended a prostate MRI. The study will measure PSA levels after 5 years to see how well the Upright MRI performs. The study is currently unclear on its recruitment status.

Study design
This is an observational study with a planned enrollment of 550 men. It compares two different MRI devices: an Upright MRI and a Standard MRI.
What's involved
You would need to be fit for all study procedures, including an ultrasound-guided biopsy, and able to tolerate general or spinal anesthesia. You will also have a seated MRI.
Compensation
Not stated in the trial record.
Follow-up
Your PSA levels will be measured at 5 years after joining the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT03474913

Upright MRI for Prostate Cancer Screening

Recruiting
Not specifiedAges 18+Observational
Icahn School of Medicine at Mount Sinai
~550 participants
Updated 2026-01-07 on ClinicalTrials.gov
What's tested:Upright MRIStandard MRI

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
PSA levels
Measured over 5 years

Conditions

Prostate Cancer
Elevated PSA
Elevated Prostate Specific Antigen

Explore related trials

Prostate Carcinoma

Where it's being run

1 sites across 1 states
New York1

Study leadership

  • Ash Tewari, MD · PRINCIPAL_INVESTIGATOR · Icahn School of Medicine at Mount Sinai

Who to contact

Monali Fatterpekar, Ph.D.
[email protected]
(212) 241-0751
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Men at risk of prostate cancer and have been advised to have a prostate MRI.
Age ≥ 18 years.
Fit for undergoing all study protocol procedures which includes an ultrasound guided biopsy.
Able to tolerate general or spinal anesthesia.
Ability to understand and the willingness to sign a written informed consent and to comply with the protocol.

Exclusion

Patients who have been treated using 5- alpha-reductase inhibitors at the time of study enrollment or 6 months prior to enrollment.
Patients with previous history of prostate biopsy, prostate surgery or treatment for prostate cancer (interventions for benign prostatic hyperplasia/bladder outflow obstruction is acceptable)
Patients who have evidence of a urinary tract infection or history of acute prostatitis within the last 3 months.
Patients contraindicated to undergoing the MRI procedure e.g. pacemaker, estimated GFR\<=50, automatic implantable cardiac defibrillators.
History of any other medical condition precluding procedures described in the protocol

What this trial measures

  • PSA levels5 years

    Prostate-specific Antigen (PSA) levels